TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01016262

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MAX-002
Description: MAX-002 suppository 1 gram (g) rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the open-label (OL) phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo suppository rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canasa®
Description: Canasa® suppository 1 g rectally once daily at bedtime for 6 weeks during the DB phase. Participants will then receive either MAX-002 suppository, standard care treatment or no treatment (as per Investigator's judgment) for 8 weeks during the OL phase.
Study: NCT01914770

Intervention type: DRUG
Intervention: Belimumab 1 mg/kg
Description: Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).

Intervention type: DRUG
Intervention: Belimumab 10 mg/kg
Description: Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).

Intervention type: DRUG
Intervention: Placebo
Description: Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
Study: NCT02237677

Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging

Intervention type: OTHER
Intervention: Positron emission tomography (PET) imaging
Description: Positron emission tomography (PET) imaging
Study: NCT01022905

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvanted influenza A(H1N1) vaccines
Description: Immunization (1-2 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adjuvanted influenza A(H1N1) vaccines
Description: Immunization (1-2 doses)
Study: NCT00446888

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Meals for Diet Stabilization
Description: Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Meals for Diet Stabilization
Description: Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Forticare
Description: 400 ml of commercially-available nutritional supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Product 4808
Description: 400 ml Forticare, to which has been added extra protein and the amino acid leucine.
Study: NCT00307762

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intensified gait trainer
Description: Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: intensified gait trainer
Description: Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
Study: NCT02764268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Study: NCT02702323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TACE
Description: one times every 4-6 weeks.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: one times every 4-6 weeks.
Study: NCT02859090

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: tonsillectomy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study: NCT01886287

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Octreotide LAR
Description: Octreotide LAR as outlined in Treatment Arm.
Study: NCT03106454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate
Description: Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone
Description: Norethindrone 1.05mg
Study: NCT03799744

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Dose level 1: 3.3x10\^12 viral particles/patient and Dose level 2: 1x10\^13 viral particles/patient

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: VCN-01
Description: Dose level 1: 3.3x10\^12 viral particles/patient and Dose level 2: 1x10\^13 viral particles/patient

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Dose: 1500 mg Q4W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Dose: 1500 mg Q4W
Study: NCT01285700

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamazym
Description: ERT, infusion weekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamazym
Description: ERT, infusion weekly
Study: NCT00922688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptide Alanyl-Glutamine
Description: Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipeptide Alanyl-Glutamine
Description: Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
Study: NCT01078961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given intravenously on days 1, 8 and 15 of each 28 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib
Description: 400mg taken orally twice a day
Study: NCT04408352

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: selective bladder denervation using RF energy
Description: RF ablation of the trigone for the treatment of UUI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: selective bladder denervation using RF energy
Description: RF ablation of the trigone for the treatment of UUI
Study: NCT01680081

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adenosine stress dynamic CT perfusion
Study: NCT04646356

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus capsule (low-dose)
Description: low-dose Tacrolimus will be given for 6 months followed by a washout period for 6 months
Study: NCT01570257

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus
Description: in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
Study: NCT02584270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Palatal Augmentation Prosthesis (PAP)
Description: The palatal augmentation prosthesis, or PAP can improve speech and swallowing functions through reshaping the palatal contours. This may improve the contact between the tongue and hard palate as a person speaks or eats. It is meant to be created after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.

Intervention type: OTHER
Group type: OTHER
Intervention: Articulation Therapy
Description: Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Articulation Therapy
Description: Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
Study: NCT00289224

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bivalent killed whole cell oral cholera vaccine
Description: Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:~V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS
Study: NCT04791098

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Specific infectious diseases consultation
Description: Specific infectious diseases consultation at Clermont Ferrand Hospital with a specialist doctor :~* Update vaccinations~* Advice to travelers~* Diagnostic and treatment of latent tuberculosis infection
Study: NCT00532207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: teriparatide
Description: subcutaneous 20 micrograms
Study: NCT02510833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercises oriented, manual and monitoring by phone
Description: Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercises oriented, manual and without monitoring by phone
Description: Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
Study: NCT01824589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: -7 cm H2O ITPR
Description: Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: -7 cm H2O ITPR
Description: Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
Study: NCT00289224

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
Study: NCT04785898

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ID Now™ COVID-19 Screening Test
Description: Patients, meeting the eligibility criteria, are selected consecutively in the emergency room. The investigating doctor delivers the written information note, answers the patient's questions and obtains his free, informed and express consent. The patient has sufficient time to reflect to make the decision to participate in the study. His oral, free, informed and express consent will be traced in the computerized medical file on the day of its inclusion in the COVID-IDNow protocol. Each patient participating in the study retains the possibility of participating simultaneously in another research. No exclusion period is provided for in the protocol.
Study: NCT01824589

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: -12cm H2O ITPR
Description: Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: -12cm H2O ITPR
Description: Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
Study: NCT03133832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Companion Tablet
Description: Chinese-made drug for schistosomiasis treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Companion Tablet
Description: Chinese-made drug for schistosomiasis treatment
Study: NCT04002791

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VasoBand
Description: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: VasoBand
Description: Dual-bladder radial artery hemostatic compression device capable of ipsilateral ulnar artery compression
Study: NCT04002726

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inter-grader agreement (IGA) app
Description: A smartphone-based app with images of conjunctivae for trachoma grading training purposes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inter-grader agreement (IGA) app
Description: A smartphone-based app with images of conjunctivae for trachoma grading training purposes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inter-grader agreement (IGA) app
Description: A smartphone-based app with images of conjunctivae for trachoma grading training purposes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inter-grader agreement (IGA) app
Description: A smartphone-based app with images of conjunctivae for trachoma grading training purposes.
Study: NCT03133832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Companion Tablet
Description: Chinese-made drug for schistosomiasis treatment
Study: NCT04592549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM03820
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM03820
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM03820
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM03820
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADM03820
Description: ADM03820 is a 1:1 mixture of two human IgG1 non-competitive binding anti-SARS-CoV-2 antibodies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT02263053

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POSTERIOR MOBILIZATION
Description: Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAUDAL MOBILIZATION
Description: Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
Study: NCT02121964

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsulectomy in Direct Anterior Total Hip Arthroplasty
Description: Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Capsulotomy in Direct Anterior Total Hip Arthroplasty
Description: Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
Study: NCT02604082

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vibrocompression (VB)
Description: Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hyperinflation (HMV)
Description: Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HMV+VB
Description: Association between Vibrocompression and Hyperinflation with mechanical ventilator
Study: NCT04385706

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Applied Coaching Model
Description: The Applied Coaching Model incorporates key learning opportunities and coaching strategies with evidence-based practices, approaches and theories and will serve as a tool for all healthcare providers wanting to implement coaching techniques within their practice.
Study: NCT03101462

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated Influenza Vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Live Attenuated Influenza Vaccine
Study: NCT00953277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Processed Human Nerve Tissue Scaffold
Description: Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
Study: NCT02757677

Intervention type: DEVICE
Intervention: Optical Coherence Tomography based Angiography
Description: A contrast-free, noninvasive technology to identify blood vessels in the eye

Intervention type: DEVICE
Intervention: Optical Coherence Tomography based Angiography
Description: A contrast-free, noninvasive technology to identify blood vessels in the eye

Intervention type: DEVICE
Intervention: Optical Coherence Tomography based Angiography
Description: A contrast-free, noninvasive technology to identify blood vessels in the eye
Study: NCT02642692

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patellar Tendon graft
Description: Acl reconstruction with patellar tendon graft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hamstring Graft
Description: Acl reconstruction with hamstring graft
Study: NCT02740725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching Therapy
Description: Occlusion of a dominant eye with better best corrected visual acuity

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching Therapy
Description: Occlusion of a dominant eye with better best corrected visual acuity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interactive Binocular Treatment System
Description: Dissociation of two eyes with more foveal stimulation to the amblyopic eye
Study: NCT01912404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 25 mg BID for 28 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo controlled
Study: NCT01138618

Intervention type: DEVICE
Intervention: Venous blod sample
Description: Regular venous blood sample withdrawn from the laboratory

Intervention type: DEVICE
Intervention: Venous blod sample
Description: Regular venous blood sample withdrawn from the laboratory

Intervention type: DEVICE
Intervention: CHEMPAQ
Description: Capillary blood sample analyzed by CHEMPAQ

Intervention type: DEVICE
Intervention: CHEMPAQ
Description: Capillary blood sample analyzed by CHEMPAQ
Study: NCT00924742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tapimycin (piperacillin 4 g + tazobactam 0.5g)
Description: One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing